Form 4: Mary Ellen Coe Reports Merck & Co. Stock Transactions

Mary Ellen Coe, a Director at Merck & Co., Inc., reported transactions involving phantom stock units and common stock.

Summary

• Mary Ellen Coe, a Director at Merck & Co., Inc. (MRK), reported a transaction on May 29, 2026.
• The transaction involved the acquisition of 1,853.0997 phantom stock units, which are to be settled in cash upon termination of service.
• These phantom stock units are linked to Merck & Co. common stock.
• Following the transaction, Coe beneficially owns 31,765.6386 units of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine insider transactions and does not indicate significant positive or negative shifts in the company's outlook or the insider's conviction.

Positives

• Director Mary Ellen Coe continues to hold a significant beneficial ownership of Merck & Co. common stock.
• The acquisition of phantom stock units indicates continued engagement and potential future value realization for the reporting person.

Risks

• Phantom stock units are subject to settlement in cash upon termination of service, meaning the value is realized at that point and is subject to market fluctuations until then.
• The value of phantom stock units is tied to the performance of Merck & Co. common stock, exposing the reporting person to market risk.

Future Outlook

The filing does not contain forward-looking statements or guidance. It reports on past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the holdings and activities of company directors and officers. This filing by a Merck & Co. director is typical for monitoring insider sentiment and ownership changes within the pharmaceutical sector.

Stakeholder Impact

• Shareholders: Provides transparency into director's stock holdings and transactions, which can inform investment decisions.
• Employees: Indirectly reflects the company's ongoing compensation and incentive structures for its leadership.
• Management: Confirms continued participation and potential financial interest in the company's performance by a key director.

Key Dates

Keywords

Form 4, SEC Filing, Merck & Co., MRK, Director, Stock Transaction, Phantom Stock, Beneficial Ownership, Insider Trading